Steno Diabetes Center, Gentofte, Denmark.
Kidney Int. 2011 May;79(10):1113-8. doi: 10.1038/ki.2010.554. Epub 2011 Jan 26.
Recent studies have shown that both glomerular and tubulointerstitial damage are important factors in the pathophysiology and progression of diabetic nephropathy. To examine whether markers of tubular damage are useful in monitoring the progression of disease, we measured urinary levels of neutrophil gelatinase-associated lipocalin (NGAL), liver-fatty acid-binding protein (LFABP), and kidney injury molecule-1 (KIM-1) in a 3-year intervention study of 63 type 1 diabetic patients with kidney disease. The baseline mean glomerular filtration rate (GFR) was 87 ml/min per 1.73 m(2) and urinary albumin excretion 1141 mg/24 h. Patients with the highest compared with the lowest quartile of urinary NGAL at baseline had higher urinary KIM-1 levels and a significant decrease in their GFR each year. Using linear regression analysis, we found that elevated urinary NGAL and KIM-1 concentrations were associated with a faster decline in GFR, but not after adjustment for known promoters of progression. Urinary LFABP was not related to decline in GFR. Losartan treatment (100 mg/day) reduced urinary KIM-1 by 43% over a 12-month period. Thus, urine biomarker measurements in patients with type 1 diabetic nephropathy did not provide additional prognostic information to that of known progression promoters.
最近的研究表明,肾小球和肾小管间质损伤都是糖尿病肾病病理生理学和进展的重要因素。为了研究肾小管损伤标志物是否有助于监测疾病进展,我们在一项为期 3 年的 63 例 1 型糖尿病肾病患者的干预研究中,测量了尿中性粒细胞明胶酶相关脂质运载蛋白(NGAL)、肝脂肪酸结合蛋白(LFABP)和肾损伤分子-1(KIM-1)的水平。基线时平均肾小球滤过率(GFR)为 87ml/min/1.73m2,尿白蛋白排泄率为 1141mg/24h。与基线时尿 NGAL 最高四分位数相比,最低四分位数的患者尿 KIM-1 水平更高,每年 GFR 下降更明显。线性回归分析发现,尿 NGAL 和 KIM-1 浓度升高与 GFR 下降更快相关,但在调整已知进展促进剂后则不然。尿 LFABP 与 GFR 下降无关。氯沙坦治疗(100mg/天)可使尿 KIM-1 在 12 个月内降低 43%。因此,1 型糖尿病肾病患者的尿液生物标志物测量并未提供比已知进展促进剂更多的预后信息。